JP2018505899A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505899A5
JP2018505899A5 JP2017543785A JP2017543785A JP2018505899A5 JP 2018505899 A5 JP2018505899 A5 JP 2018505899A5 JP 2017543785 A JP2017543785 A JP 2017543785A JP 2017543785 A JP2017543785 A JP 2017543785A JP 2018505899 A5 JP2018505899 A5 JP 2018505899A5
Authority
JP
Japan
Prior art keywords
alzheimer
disease
mammal
condition
cognitive dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017543785A
Other languages
English (en)
Japanese (ja)
Other versions
JP6830895B2 (ja
JP2018505899A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/018305 external-priority patent/WO2016134042A2/en
Publication of JP2018505899A publication Critical patent/JP2018505899A/ja
Publication of JP2018505899A5 publication Critical patent/JP2018505899A5/ja
Application granted granted Critical
Publication of JP6830895B2 publication Critical patent/JP6830895B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017543785A 2015-02-18 2016-02-17 ストレス誘発性p−tauを低下させるトリアゾロピリジン及びトリアゾロピリミジン Active JP6830895B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562117888P 2015-02-18 2015-02-18
US62/117,888 2015-02-18
PCT/US2016/018305 WO2016134042A2 (en) 2015-02-18 2016-02-17 Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau

Publications (3)

Publication Number Publication Date
JP2018505899A JP2018505899A (ja) 2018-03-01
JP2018505899A5 true JP2018505899A5 (enExample) 2019-03-14
JP6830895B2 JP6830895B2 (ja) 2021-02-17

Family

ID=56692299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543785A Active JP6830895B2 (ja) 2015-02-18 2016-02-17 ストレス誘発性p−tauを低下させるトリアゾロピリジン及びトリアゾロピリミジン

Country Status (8)

Country Link
US (2) US10618899B2 (enExample)
EP (1) EP3259274B1 (enExample)
JP (1) JP6830895B2 (enExample)
KR (1) KR102220260B1 (enExample)
CN (1) CN107709326B (enExample)
AU (1) AU2016220049C1 (enExample)
CA (1) CA2976258C (enExample)
WO (1) WO2016134042A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107709326B (zh) 2015-02-18 2021-12-17 巴克老龄问题研究所 降低应激诱导的p-tau的三唑并吡啶和三唑并嘧啶
WO2020231723A1 (en) 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
ES2932481B2 (es) * 2021-07-09 2023-09-11 Consejo Superior Investigacion Compuestos inhibidores de la quinasa de tau y tubulina (ttbk)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2174080A1 (en) 1993-10-12 1995-04-20 Paul Edward Aldrich 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US6107300A (en) * 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
WO1999011643A1 (en) * 1997-09-02 1999-03-11 Du Pont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
KR20030016222A (ko) 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 수술후 스트레스 예방ㆍ치료제
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
AU2011291506B2 (en) 2010-08-19 2016-07-28 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
AU2012290116B2 (en) 2011-08-02 2016-11-03 Buck Institute For Research On Aging Tropinol esters and related compounds to promote normal processing of APP
WO2013026021A2 (en) 2011-08-18 2013-02-21 Buck Institute For Research On Aging Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease
USRE49873E1 (en) 2012-03-19 2024-03-19 Buck Institute For Research On Aging APP specific bace inhibitors (ASBIs) and uses thereof
US9649317B2 (en) * 2012-09-19 2017-05-16 The Trustees Of The University Of Pennsylvania Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies
WO2014127042A1 (en) 2013-02-12 2014-08-21 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
CN107709326B (zh) 2015-02-18 2021-12-17 巴克老龄问题研究所 降低应激诱导的p-tau的三唑并吡啶和三唑并嘧啶

Similar Documents

Publication Publication Date Title
JP2017075173A5 (enExample)
MX2021002321A (es) Nuevos metodos.
AR110747A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
JP2018021046A5 (enExample)
JP2016518337A5 (enExample)
AR111693A1 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
JP2014507446A5 (enExample)
JP2015155440A5 (enExample)
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
JP2011509252A5 (enExample)
RU2017105353A (ru) Соединения
JP2016522254A5 (enExample)
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
JP2016512817A5 (enExample)
JP2017524735A5 (enExample)
JP2017518982A5 (enExample)
RU2019100037A (ru) Способ лечения рассеянного склероза с использованием ингибитора lsd1
JP2016501219A5 (enExample)
JP2015537009A5 (enExample)
JP2016537338A5 (enExample)
JP2016537432A5 (enExample)
JP2019085364A5 (enExample)
RU2018122012A (ru) БИС-пиридазиновые соединения и их применение в лечении рака
FR3047665B1 (fr) Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees